Our INGRESS colleagues Mahmoud Hashim, Robert Bartsch, and Bart Heeg have just published a new paper (see link below) in the journal Value in Health where they evaluate the relationship between surrogate (PFS, ORR) and hard endpoints OS in advanced NSCLC studies that did not allow for crossover or reported balanced post-progression treatments. Very well done to them!

To find out more about the team, see the INGRESS company website

You can find the article here.